Incyte Corporation Revenue and Competitors
Estimated Revenue & Valuation
- Incyte Corporation's estimated annual revenue is currently $2.9B per year.
- Incyte Corporation's estimated revenue per employee is $1,016,061
- Incyte Corporation's total funding is $3.5M.
- Incyte Corporation's current valuation is $16.5B. (January 2022)
Employee Data
- Incyte Corporation has 2864 Employees.
- Incyte Corporation grew their employee count by 10% last year.
Incyte Corporation's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Regional VP, General Manager | Reveal Email/Phone |
2 | Associate VP Clinical Pharmacology | Reveal Email/Phone |
3 | Associate VP, Clinical Research Scientist, Inflammation & Autoimmunity | Reveal Email/Phone |
4 | Associate VP, Biotherapeutics | Reveal Email/Phone |
5 | Group VP, US Medical Affairs | Reveal Email/Phone |
6 | Group VP, Head Biology | Reveal Email/Phone |
7 | Group VP, Head Early Clinical Development | Reveal Email/Phone |
8 | Associate VP, Corporate Counsel, Business Development and Alliance Management | Reveal Email/Phone |
9 | Associate VP, North American Legal | Reveal Email/Phone |
10 | Associate VP | Reveal Email/Phone |
Incyte Corporation Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $34M | 169 | 8% | N/A | N/A |
#2 | $8.4M | 42 | -28% | N/A | N/A |
#3 | $68.7M | 342 | 6% | N/A | N/A |
#4 | $49.4M | 246 | -10% | N/A | N/A |
#5 | $7.8M | 39 | 44% | N/A | N/A |
#6 | $148.3M | 738 | 8% | N/A | N/A |
#7 | $24.7M | 123 | 13% | N/A | N/A |
#8 | $0.8M | 8 | 14% | N/A | N/A |
#9 | $9M | 45 | 7% | N/A | N/A |
#10 | $3.8M | 19 | -50% | N/A | N/A |
What Is Incyte Corporation?
Incyte\'s vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have an experienced management and discovery team. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in healthcare, improve the lives of patients and build significant sustainable value for our shareholders.
keywords:N/A
$3.5M
Total Funding
2864
Number of Employees
$2.9B
Revenue (est)
10%
Employee Growth %
$16.5B
Valuation
N/A
Accelerator
Incyte Corporation News
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan. INCY | 6 hours ago. Incyte (NASDAQ:INCY) and Maruho Co.,...
Incyte Corporation INCY is scheduled to release first-quarter 2022 results on May 3, before the market opens. The company's earnings...
Incyte Corporation (INCY) stock is down -8.42% over the last 12 months, and the average rating from Wall Street analysts is a Buy.
INDIANAPOLIS, Sept. 30, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily OLUMIANT® (baricitinib) 4-mg was superior to placebo in achieving significan ...
∙ ∙ ∙ ∙ 2 Attachments Original document Permalink Disclaimer Incyte Corporation published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2021 18:33:05 UTC.
Other Companies in Wilmington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $728.8M | 2892 | 3% | N/A |
#2 | $992.7M | 2918 | N/A | N/A |
#3 | $1299.4M | 3043 | N/A | N/A |
#4 | N/A | 3810 | N/A | N/A |
#5 | $1676.8M | 4436 | 0% | N/A |